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Oncology is one of the few areas of medicine where most patients are treated intravenously rather than receiving oral drugs.
Recently, several oral anti-cancer drugs have been approved and there are many more in development. Oral chemotherapy is
attractive because of its convenience and ease of administration, particularly in the palliative setting. With an increasing number
of oral agents emerging, we can expect to see a rapid rise in the use of oral chemotherapy in years to come. This article
reviews recent developments in oral chemotherapy, both of traditional cytotoxics and novel, targeted agents, from the
viewpoint of patients, physicians, drug developers and health-care providers.
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Oncology is one of the few areas of medicine where most patients
are treated intravenously (i.v.) rather than receiving oral drugs.
Recently, several oral anti-cancer drugs have been approved and
there are many more in development. Oral chemotherapy is attrac-
tive because of its convenience and ease of administration,
particularly in the palliative setting (Payne, 1992; Liu et al,
1993). It is also especially appropriate where prolonged drug expo-
sure is desirable as with schedule dependent agents such as
topoisomerase I inhibitors or the ﬂuoropyrimidines. The same
argument applies to novel agents such as signal transduction inhi-
bitors and anti-angiogenic drugs that may need to be taken daily
for months or years in contrast to the intermittent, short term
use of conventional antiproliferative cytotoxics that are often well
suited to i.v. administration. With an increasing number of oral
agents emerging, we can expect to see a rapid rise in the use of oral
chemotherapy in years to come. It is, therefore, timely to consider
whether this represents a major change of direction or just a
passing fashion in cancer treatment.
More than 20 oral cytotoxics are already available, so why have
we remained so reliant on i.v. chemotherapy? One reason is that
many oral cytotoxics are new formulations of existing compounds.
These are often low-priced ‘generics’ that have not been a high
sales priority for the major pharmaceutical companies (Table 1).
For example, cyclophosphamide has been given orally for many
years in women with breast cancer as part of some CMF regimens.
Oral etoposide is active against a wide range of tumours but enthu-
siasm for its use has been limited by concerns over toxicity.
Currently, probably the widest use of oral chemotherapy is with
6-mercaptopurine, methotrexate and busulphan in patients with
leukaemia and lymphoma. A second factor limiting the use of
newer oral chemotherapy agents has been the narrow clinical
setting in which their use is indicated. This has limited the impact
of drugs such as temozolamide (approved for glioma, astrocytoma
and melanoma only in the UK) and idarubicin (principally used in
leukaemia). Similarly, capecitabine was initially licenced only for
use in women with advanced breast cancer that was resistant to
taxanes. Another factor, more difﬁcult to deﬁne, is perhaps that
amongst both clinicians and drug developers there has been an
implicit assumption that anticancer drugs are best given i.v.
CYTOTOXICS
Over the last decade oral chemotherapy has generally failed to keep
pace with increasing use of i.v. cytotoxics. Japan is an exception
where there has been widespread use of oral chemotherapy, espe-
cially in patients with gastrointestinal cancers, during the mid-
1990s. Elsewhere, however, the continued dominance of i.v. treat-
ment reﬂects in part the range of new drugs and also novel
classes of agent that have been available for i.v. use.
Many emerging oral cytotoxics are new formulations of drugs
routinely given i.v. (Table 2). Topotecan is equally effective in
small cell lung cancer by the i.v. and oral routes but oral treatment
has a better toxicity proﬁle with less myelosuppression (von Pawel
et al, 2001). The ability to administer taxanes orally would offer
considerable advantages, particularly with paclitaxel where the
chremophore EL vehicle can be responsible for hypersensitivity
reactions. Coadministration of cyclosporin A, a potent inhibitor
of p-glycoprotein, results in oral bioavailability for taxanes in
excess of 50%. Several oral taxanes are also in development (Polizzi
et al, 2000; Rose et al, 2001) and likely to become available in the
next few years.
Because 5-ﬂuorouracil (5-FU) is highly schedule dependent, but
oral administration is unreliable and causes diarrhoea, this has
been a particular focus of efforts to develop oral alternatives.
These have included pro-drugs that are absorbed unchanged
(capecitabine, tegafur), addition of inhibitors of the enzyme
DPD that catabolises 5-FU (uracil, eniluracil), or a combination
of the two (UFT, S1, emitefur) (reviewed by Lamont and Schilsky,
1999). Despite the elegance of these approaches, their develop-
ment has not been straightforward. Eniluracil is a very effective
DPD inhibitor that renders 5-FU highly bioavailable after oral
administration but development has been suspended on the basis Received 22 May 2002; revised 15 August 2002; accepted 15 August 2002
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UFT and folinic acid is active in ﬂuoropyrimidine sensitive
tumours but has not been approved for use in the US with
doubts regarding its efﬁcacy in relation to i.v. 5-FU remaining.
The future of S1 and emitefur is also unclear. The exception is
capecitabine which is now approved across the world in two
common solid tumours, breast and colorectal cancer. Capecitabine
is as effective as the ‘Mayo Clinic’ i.v. regimen of 5-FU in meta-
static colorectal cancer, achieving higher response rates with equal
time to progression and overall survival. It is also active as a
single agent in taxane resistant breast cancer. Results of a recent
trial in patients with anthracycline resistant breast cancer show
that the addition of capecitabine to docetaxal signiﬁcantly
prolongs survival (O’Shaughnessy et al, 2002). The success of
capecitabine means that the proﬁle of oral chemotherapy is set
to rise.
NOVEL AGENTS
Potentially even more important in the medium and long-term
will be ‘smart’ drugs, targeted to components of intra-cellular
signalling pathways such as protein kinases (Rajagonopalan et
al, 2000). Several are being developed as oral therapies with
imatinib and iressa leading the way (Table 3). Imatinib inhibits
the c-abl and c-kit tyrosine kinases. It has excellent oral bioavail-
ability and remarkable activity in both CML (Kantarjian and
Talpaz, 2001) and G.I. stromal tumours (van Oosterom et al,
2001), which are ‘driven’ by the bcr-able fusion protein and c-
kit, respectively. Iressa (ZD 1839) is an oral anilinoquinazoline
inhibitor of EGFR tyrosine kinase activity given once daily by
mouth that is active in non-small cell lung cancer (Baselga et
al, 2000). A reversible acneiform rash has been observed with
both iressa and tarceva (OSI-774), another oral quinazoline
EGFR tyrosine kinase inhibitor also active in non-small cell lung
and head and neck cancers (Perez-Soler et al, 2001; Senzer et al,
2001). The same rash is seen with cetuximab, an i.v. monoclonal
antibody targeted at the EGFR receptor (Baselga, 2001). This
overlap in toxicities between oral and i.v. compounds with
distinct molecular characteristics emphasises that route of admin-
istration alone will not necessarily avoid a ‘class effect’ toxicity.
PERSPECTIVES ON THE DEVELOPMENT OF ORAL
ANTI-CANCER DRUGS
Notwithstanding these developments, the future of oral anti-cancer
treatments is not entirely clear. Concerns remain regarding compli-
ance, absorption and variable pharmacokinetics as well as re-
imbursement in some countries. Perspectives on the use of oral
chemotherapy differ between the patient, the oncologist, the phar-
maceutical industry and the funders of health care.
The patient
A clear majority (480%) of patients prefer oral chemotherapy,
but only provided this is not at the expense of efﬁcacy (Liu et
al, 1993; Borner et al, 2002). The preference for oral
chemotherapy stems largely from the greater convenience of
treatment at home (cited by 57% of patients) and avoidance
of venepunctures (55%). There are additional concerns with
protracted infusional regimens where many patients experience
problems with indwelling venous catheters. A third of patients
also cited the greater sense of ‘control’ over their treatment that
they would gain from oral chemotherapy (Liu et al, 1993).
Table 3 Some oral novel agents in development
Agent Comment
MMPI
Col-3 Tetracyclin analogue
TKI
STI571/imatanib Inhibits bcr-abl and PDGF TKs
ZD1839/Iressa
OSI774/tarceva
SU006668 Multiple receptor TK inhibitor
CEP-701 Neurotrophin R linked TK inhibitor
FTI
BMS294662 Inhibits prenylation of ras
Antiangiogenics
SU5416 Inhibitor of VEGF-mediated signaling
PTK787 Inhibitor of VEGF-mediated signaling
TAS-102 Antitumour/antiangiogenic
Others
Phenylbutyrate
CP-461 Inhibitor of c-GMP phosphodiesterases
PKC412 Inhibitor of Protein Kinase C
MMPI=matrix metalloprotease inhibitor; TKI=tyrosine kinase inhibitor; FTI-farnesyl
transferase inhibitor.
Table 2 Some oral cytotoxic chemotherapy agents in development
Agent Comment
Camptothecins
Topotecan Bioavailability *40%
Irinotecan
Rubitecan
BN80915 More potent topoisomerase I inhibitor
Taxanes
Paclitaxel/GF120918 p-gp modulator
Paclitaxel/valspodar p-gp modulator
Taxotere/Cyclosporin A p-gp modulator
BMS-275183 Novel oral taxane
Antimetabolite
CS-682 Deoxycytidine-type antimetabolite
S-1 Oral ﬂuoropyrimidine
Trimetrexate
Table 1 Some approved oral chemotherapy drugs
Compound Comment
Cyclophosphamide 70–80% bioavilability, less nausea
Other alkylators Main use in haemoto-oncology
Procarbazine
Melphalan
Chlorambucil
Busulphan
Lomustine
Etoposide Similar toxicity
Idarubicin Less cardiotoxicity
Pyrimidine antimetabolites
5-FU Low bioavailability
UFT Tegafur and uracil combination
Capecitabine Prodrug; similar toxicity to infusional 5-FU
Other antimetabolites
Mercaptopurine
Thioguanine
Methotrexate
Hydroxyurea
Temozolomide Imidazotetrazine derivative
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and oral treatment can reduce the disruption of home life for
both the patient and their family (Payne, 1992; De Mario
and Ratain, 1998). Similar considerations apply in the adjuvant
setting where patients are seeking to resume their normal life-
style following diagnosis and primary treatment.
Taking treatment at home over a prolonged period does,
however, present challenges. It is often said that for some
patients reduced contact with the oncology team may be a disad-
vantage if it limits the support they receive, although there is
little evidence to support this assertion. More easy to deﬁne is
the importance of educating patients. Experience with capecita-
bine has shown it is essential that patients recognise side-
effects so that treatment can be interrupted, preventing these
toxicities becoming more serious (Cassidy et al, 1999). Education
of the patient, as well as their G.P., practice nurse and pharma-
cist, will be of crucial importance where anticancer drugs are
being taken primarily in the community rather than at the
hospital.
The oncologist
From the medical perspective, oral chemotherapy requires us to
look at many of our preconceptions about cancer treatment. Like
our patients, as oncologists we want oral treatment to be as
effective as i.v. therapy with no increase in toxicity, especially
vomiting and diarrhoea. Oncologists recognise that in breast
cancer responses to endocrine therapy are longer lasting and
achieved with less toxicity than with chemotherapy, but there
is often a prejudice that in other settings i.v. treatment is inher-
ently more reliable and more effective. A more substantive
concern is that oral drugs may have low and unpredictable bioa-
vailability in contrast to the immediate and complete
bioavailability after i.v. administration. Variable oral bioavailabil-
ity is likely to be a function of variable degradation in
gastrointestinal ﬂuids, intestinal P-glycoprotein and interaction
with intestinal and liver cytochrome P450 (CYP3A4) catalytic
activity which varies as much as 10-fold among individuals
(Guengerich, 1992). In addition, some drugs, such as etoposide,
exhibit saturable absorption so bioavailability is much lower at
high doses. This does not limit the use of oral etoposide at stan-
dard doses, but does complicate the widespread of oral
leucovorin, which demonstrates only 31% bioavailability at a
200 mg dose.
This concern regarding bioavailability is understandable for a
class of drugs with a narrow therapeutic index, but is perhaps exag-
gerated in relation to the evidence. Despite direct intravascular
delivery, the pharmacokinetics of i.v. cytotoxics vary widely.
Indeed, when the pharmacokinetics of i.v. and oral idarubicin were
compared, there was substantial variability in kinetics using both
routes of administration. Improved methods of formulation and
drug delivery along with fractionated dosing should overcome
many of these pharmacokinetic problems.
Compliance is a major consideration in any large scale shift to
oral anticancer treatment. These concerns are usually voiced by
oncologists rather than their patients. Reports on compliance
are, however, conﬂicting. Intuitively, and in view of the serious-
ness of their condition, patients with cancer might be thought a
group unlikely to default on treatment. High rates of compliance
were shown using an innovative electronic tablet bottle in
patients with lymphoma, small cell lung cancer and ovarian
cancer patients (Lee et al, 1992, 1993, 1996). On the other hand,
a surprising 43% of patients receiving oral cyclophosphamide as
part of treatment for breast cancer did not take their medication
as prescribed (Lebovits et al, 1990). Interestingly, in this study
some patients took more than the prescribed dose. This
phenomenon of ‘over-compliance’ may be a concern if patients
mistake their dose or continue treatment in the face of side-
effects.
Many factors impact on treatment compliance but their impor-
tance in patients with cancer is unclear. In general, compliance is
higher in older, better educated, more afﬂuent patients living in
smaller family groups. Compliance is also improved by limiting
the number of tablets (a maximum of 6–8 per day has been
suggested), making them easy to swallow and using a simple
dosing schedule. By contrast, compliance tends to fall with chronic
administration, which may be an issue with signal transduction
inhibitors and other novel approaches. Education of the patient
and their family, daily blister packs and frequent contact with
the prescribing centre through weekly telephone calls from a nurse
specialist, should reduce non-compliance, but supportive evidence
is lacking.
With patients taking their treatment at home rather than at
the hospital, communication with health care workers in the
community will be increasingly important. It is, however,
important that trained oncologists continue to prescribe and
monitor the use of oral anticancer drugs. We must remember
the lesson of oral etoposide which caused serious toxicity;
anti-proliferative cytotoxics are potentially toxic irrespective
of the route of administration and must be carefully super-
vised. Oral agents with novel modes of action may also have
unexpected side-effects, especially as the optimum duration
of treatment is unclear and patients may remain on treatment
for many years. It may also not be clear how and when to
modify doses. The appropriate use of drugs targeted at speciﬁc
signalling pathways may require that each patient’s tumour
must undergo molecular characterisation in the oncology
centre. All of these issues require that the prescription and
monitoring of oral chemotherapy be restricted to the oncolo-
gist.
The pharmaceutical industry
Oral chemotherapy will only become available if new agents are
developed and promoted by the pharmaceutical industry. From
their perspective oral formulations may be more expensive to
develop with issues such as the effect of food on absorbtion and
drug interactions more of a concern than with their intravenous
counterparts. Oral formulations will not be appropriate or feasible
for all drugs. There is, for example, little to be gained clinically
from developing an oral form of a conventional antiproliferative
that can be given simply once every 3 weeks as a bolus i.v. injec-
tion. An early decision to develop oral compounds can be made
if their mode of action makes it clear that prolonged daily dosing
will be required.
The development of oral chemotherapy is not straightfor-
ward. Some patient populations such as those who have
undergone upper G.I. tract surgery, those with head and neck
cancer and children may not be good candidates for oral treat-
ment. Compliance may also be a concern during early trials if
apparent ‘tolerance’ is due to non compliance which could
render identiﬁcation of a safe dose difﬁcult. Other dosing
issues are also different for oral drugs and the argument for
‘ﬂat dosing’ irrespective of body surface area, is especially
strong for oral drugs. With many i.v. cytotoxics there is little
or no evidence to support adjusting doses for body surface
area, but the dose rounding that is a consequence of having
a limited number of ﬁxed table dosages will require a change
in attitude from those developing and prescribing anti-cancer
drugs.
All these factors indicate that the decision to pursue develop-
ment of an oral compound points to the need for multiple, well
designed trials and population pharmacokinetic studies. The devel-
opment of an oral anti-cancer drug is likely to require more
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development, but many of these challenges have been overcome
in other therapeutic areas. The rewards for the successful develop-
ment of effective, novel oral anti-cancer drugs are potentially
immense.
The health-care system
Funding of health-care is an issue everywhere, although the speciﬁc
concerns vary from country to country. Assuming equivalent efﬁ-
cacy, we can expect that patients would choose oral
chemotherapy but will physicians be able and willing to follow
their lead? A particular problem is that in some countries oral
treatment may generate less income for the hospital and the
doctor.
Oral treatment will reduce the number of in-patient and out-
patient hospital visits with their associated medical and nursing
administrative costs, avoid the expense of disposables (e.g. infusion
equipment, pumps) and decrease the pharmacy workload (Twelves
et al, 2001). Currently, chemotherapy costs account for only a
small proportion of the direct cost of cancer care so it should be
possible to set increased drug costs against the substantial savings
that will be made elsewhere. Drug budgets are, however, easily
identiﬁed and this process will be easier in some countries than
in others.
Differences in methods of reimbursement and physician remu-
neration between Europe and the United States mean that
American oncologists may be less enthusiastic about oral
chemotherapy. Medicare has generally not reimbursed costs of oral
chemotherapy, except where the oral formulation is a form of the
i.v. drug. This has had clear implications for the use of oral
chemotherapy. In the world’s major market the recent agreement
by Medicare to reimburse the cost of capecitabine in the palliative
setting signals an important shift in attitude. An interesting analogy
can be drawn with the use of oral as opposed to intravenous
gancyclovir in the treatment of CMV retinitis. Although the oral
drug costs were substantially higher, overall a signiﬁcant cost
differential emerged in favour of oral therapy in terms of adminis-
trating treatment, monitoring the patient and managing adverse
events (Sullivan et al, 1996). The net result is that oral gancyclovir
therapy increases revenues for the manufacturer but reduces reven-
ues for the proﬁt-making health care providers. If the same is true
for oral chemotherapy there will be a substantial impact on the
provision of health care.
CONCLUSIONS
The outlook for oral chemotherapy is positive. Having been for
many years the poor relation, oral chemotherapy is poised to
become a major force. Encouraging clinical trial results indicate
that for the ﬁrst time many of the oral anti-cancer drugs in devel-
opment are actually better drugs rather than pale imitations of i.v.
treatments. Many of these new agents, especially signal transduc-
tion inhibitors or angiogenesis inhibitors, will be available only
as oral treatments with an i.v. dosage form either impractical or
inappropriate.
In an era when patients are increasingly well informed and
consumerism plays a more prominent role in health care,
patients’ preference for oral treatment is a powerful force. Both
the patients and their doctors will, however, only embrace oral
chemotherapy so long as it is as effective as i.v. treatment. For
the pharmaceutical industry substantial hurdles remain in the
development of oral anti-cancer drugs. Nevertheless, the large
pharmaceutical companies are investing heavily in oral drug
development. When approved, these oral agents will receive
correspondingly large marketing support building on the prefer-
ence of patients for oral treatment. This will present doctors and
others involved in delivering anti-cancer treatment with chal-
lenges in terms of re-organising structures to deliver oral
treatment.
Not all new agents will be oral and there are many exciting
novel compounds that are given i.v. Intravenous administration
will remain an important route of delivery, but we can expect oral
chemotherapy to have an increasing impact over the next years. In
the longer term, oral chemotherapy may well be the rule rather
than the exception.
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